263 related articles for article (PubMed ID: 28033443)
1. Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer.
Neidhardt G; Hauke J; Ramser J; Groß E; Gehrig A; Müller CR; Kahlert AK; Hackmann K; Honisch E; Niederacher D; Heilmann-Heimbach S; Franke A; Lieb W; Thiele H; Altmüller J; Nürnberg P; Klaschik K; Ernst C; Ditsch N; Jessen F; Ramirez A; Wappenschmidt B; Engel C; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
JAMA Oncol; 2017 Sep; 3(9):1245-1248. PubMed ID: 28033443
[TBL] [Abstract][Full Text] [Related]
2. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer.
Weber-Lassalle N; Hauke J; Ramser J; Richters L; Groß E; Blümcke B; Gehrig A; Kahlert AK; Müller CR; Hackmann K; Honisch E; Weber-Lassalle K; Niederacher D; Borde J; Thiele H; Ernst C; Altmüller J; Neidhardt G; Nürnberg P; Klaschik K; Schroeder C; Platzer K; Volk AE; Wang-Gohrke S; Just W; Auber B; Kubisch C; Schmidt G; Horvath J; Wappenschmidt B; Engel C; Arnold N; Dworniczak B; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
Breast Cancer Res; 2018 Jan; 20(1):7. PubMed ID: 29368626
[TBL] [Abstract][Full Text] [Related]
3. Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer.
Weber-Lassalle N; Borde J; Weber-Lassalle K; Horváth J; Niederacher D; Arnold N; Kaulfuß S; Ernst C; Paul VG; Honisch E; Klaschik K; Volk AE; Kubisch C; Rapp S; Lichey N; Altmüller J; Lepkes L; Pohl-Rescigno E; Thiele H; Nürnberg P; Larsen M; Richters L; Rhiem K; Wappenschmidt B; Engel C; Meindl A; Schmutzler RK; Hahnen E; Hauke J
Breast Cancer Res; 2019 Apr; 21(1):55. PubMed ID: 31036035
[TBL] [Abstract][Full Text] [Related]
4. FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population.
Kiiski JI; Tervasmäki A; Pelttari LM; Khan S; Mantere T; Pylkäs K; Mannermaa A; Tengström M; Kvist A; Borg Å; Kosma VM; Kallioniemi A; Schleutker J; Bützow R; Blomqvist C; Aittomäki K; Winqvist R; Nevanlinna H
Breast Cancer Res Treat; 2017 Nov; 166(1):217-226. PubMed ID: 28702895
[TBL] [Abstract][Full Text] [Related]
5. A possible role of FANCM mutations in male breast cancer susceptibility: Results from a multicenter study in Italy.
Silvestri V; Rizzolo P; Zelli V; Valentini V; Zanna I; Bianchi S; Tibiletti MG; Varesco L; Russo A; Tommasi S; Coppa A; Capalbo C; Calistri D; Viel A; Cortesi L; Manoukian S; Bonanni B; Montagna M; Palli D; Radice P; Peterlongo P; Ottini L
Breast; 2018 Apr; 38():92-97. PubMed ID: 29287190
[TBL] [Abstract][Full Text] [Related]
6. About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants.
Gutiérrez-Enríquez S; Bonache S; de Garibay GR; Osorio A; Santamariña M; Ramón y Cajal T; Esteban-Cardeñosa E; Tenés A; Yanowsky K; Barroso A; Montalban G; Blanco A; Cornet M; Gadea N; Infante M; Caldés T; Díaz-Rubio E; Balmaña J; Lasa A; Vega A; Benítez J; de la Hoya M; Diez O
Int J Cancer; 2014 May; 134(9):2088-97. PubMed ID: 24130102
[TBL] [Abstract][Full Text] [Related]
7. Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients.
Nurmi A; Muranen TA; Pelttari LM; Kiiski JI; Heikkinen T; Lehto S; Kallioniemi A; Schleutker J; Bützow R; Blomqvist C; Aittomäki K; Nevanlinna H
Int J Cancer; 2019 Nov; 145(10):2692-2700. PubMed ID: 30927251
[TBL] [Abstract][Full Text] [Related]
8. Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer.
Kiiski JI; Pelttari LM; Khan S; Freysteinsdottir ES; Reynisdottir I; Hart SN; Shimelis H; Vilske S; Kallioniemi A; Schleutker J; Leminen A; Bützow R; Blomqvist C; Barkardottir RB; Couch FJ; Aittomäki K; Nevanlinna H
Proc Natl Acad Sci U S A; 2014 Oct; 111(42):15172-7. PubMed ID: 25288723
[TBL] [Abstract][Full Text] [Related]
9. FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor.
Peterlongo P; Catucci I; Colombo M; Caleca L; Mucaki E; Bogliolo M; Marin M; Damiola F; Bernard L; Pensotti V; Volorio S; Dall'Olio V; Meindl A; Bartram C; Sutter C; Surowy H; Sornin V; Dondon MG; Eon-Marchais S; Stoppa-Lyonnet D; Andrieu N; Sinilnikova OM; ; Mitchell G; James PA; Thompson E; ; ; Marchetti M; Verzeroli C; Tartari C; Capone GL; Putignano AL; Genuardi M; Medici V; Marchi I; Federico M; Tognazzo S; Matricardi L; Agata S; Dolcetti R; Della Puppa L; Cini G; Gismondi V; Viassolo V; Perfumo C; Mencarelli MA; Baldassarri M; Peissel B; Roversi G; Silvestri V; Rizzolo P; Spina F; Vivanet C; Tibiletti MG; Caligo MA; Gambino G; Tommasi S; Pilato B; Tondini C; Corna C; Bonanni B; Barile M; Osorio A; Benitez J; Balestrino L; Ottini L; Manoukian S; Pierotti MA; Renieri A; Varesco L; Couch FJ; Wang X; Devilee P; Hilbers FS; van Asperen CJ; Viel A; Montagna M; Cortesi L; Diez O; Balmaña J; Hauke J; Schmutzler RK; Papi L; Pujana MA; Lázaro C; Falanga A; Offit K; Vijai J; Campbell I; Burwinkel B; Kvist A; Ehrencrona H; Mazoyer S; Pizzamiglio S; Verderio P; Surralles J; Rogan PK; Radice P
Hum Mol Genet; 2015 Sep; 24(18):5345-55. PubMed ID: 26130695
[TBL] [Abstract][Full Text] [Related]
10. FANCM and RECQL genetic variants and breast cancer susceptibility: relevance to South Poland and West Ukraine.
Nguyen-Dumont T; Myszka A; Karpinski P; Sasiadek MM; Akopyan H; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Kitsera N; Siekierzynska A; Southey MC
BMC Med Genet; 2018 Jan; 19(1):12. PubMed ID: 29351780
[TBL] [Abstract][Full Text] [Related]
11. Bi-allelic Recessive Loss-of-Function Variants in FANCM Cause Non-obstructive Azoospermia.
Kasak L; Punab M; Nagirnaja L; Grigorova M; Minajeva A; Lopes AM; Punab AM; Aston KI; Carvalho F; Laasik E; Smith LB; ; Conrad DF; Laan M
Am J Hum Genet; 2018 Aug; 103(2):200-212. PubMed ID: 30075111
[TBL] [Abstract][Full Text] [Related]
12. The RAD51C exonic splice-site mutations c.404G>C and c.404G>T are associated with familial breast and ovarian cancer.
Neidhardt G; Becker A; Hauke J; Horváth J; Bogdanova Markov N; Heilmann-Heimbach S; Hellebrand H; Thiele H; Altmüller J; Nürnberg P; Meindl A; Rhiem K; Blümcke B; Wappenschmidt B; Schmutzler RK; Hahnen E
Eur J Cancer Prev; 2017 Mar; 26(2):165-169. PubMed ID: 27622768
[TBL] [Abstract][Full Text] [Related]
13. Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes.
Suszynska M; Klonowska K; Jasinska AJ; Kozlowski P
Gynecol Oncol; 2019 May; 153(2):452-462. PubMed ID: 30733081
[TBL] [Abstract][Full Text] [Related]
14. Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2.
Kraus C; Hoyer J; Vasileiou G; Wunderle M; Lux MP; Fasching PA; Krumbiegel M; Uebe S; Reuter M; Beckmann MW; Reis A
Int J Cancer; 2017 Jan; 140(1):95-102. PubMed ID: 27616075
[TBL] [Abstract][Full Text] [Related]
15. Frequency of Pathogenic Germline Mutations in Early and Late Onset Familial Breast Cancer Patients Using Multi-Gene Panel Sequencing: An Egyptian Study.
Nassar A; Zekri AN; Kamel MM; Elberry MH; Lotfy MM; Seadawy MG; Hassan ZK; Soliman HK; Lymona AM; Youssef ASE
Genes (Basel); 2022 Dec; 14(1):. PubMed ID: 36672847
[TBL] [Abstract][Full Text] [Related]
16. Novel and recurrent BRCA1/BRCA2 mutations in early onset and familial breast and ovarian cancer detected in the Program of Genetic Counseling in Cancer of Valencian Community (eastern Spain). Relationship of family phenotypes with mutation prevalence.
de Juan Jiménez I; García Casado Z; Palanca Suela S; Esteban Cardeñosa E; López Guerrero JA; Segura Huerta Á; Chirivella González I; Sánchez Heras AB; Juan Fita MJ; Tena García I; Guillen Ponce C; Martínez de Dueñas E; Romero Noguera I; Salas Trejo D; Goicoechea Sáez M; Bolufer Gilabert P
Fam Cancer; 2013 Dec; 12(4):767-77. PubMed ID: 23479189
[TBL] [Abstract][Full Text] [Related]
17. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
18. FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome.
Kiiski JI; Fagerholm R; Tervasmäki A; Pelttari LM; Khan S; Jamshidi M; Mantere T; Pylkäs K; Bartek J; Bartkova J; Mannermaa A; Tengström M; Kosma VM; Winqvist R; Kallioniemi A; Aittomäki K; Blomqvist C; Nevanlinna H
Int J Cancer; 2016 Dec; 139(12):2760-2770. PubMed ID: 27542569
[TBL] [Abstract][Full Text] [Related]
19. The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: High frequency of FANCM pathogenic variants.
Schubert S; van Luttikhuizen JL; Auber B; Schmidt G; Hofmann W; Penkert J; Davenport CF; Hille-Betz U; Wendeburg L; Bublitz J; Tauscher M; Hackmann K; Schröck E; Scholz C; Wallaschek H; Schlegelberger B; Illig T; Steinemann D
Int J Cancer; 2019 Jun; 144(11):2683-2694. PubMed ID: 30426508
[TBL] [Abstract][Full Text] [Related]
20. Germline RAD51C mutations in ovarian cancer susceptibility.
Coulet F; Fajac A; Colas C; Eyries M; Dion-Minière A; Rouzier R; Uzan S; Lefranc JP; Carbonnel M; Cornelis F; Cortez A; Soubrier F
Clin Genet; 2013 Apr; 83(4):332-6. PubMed ID: 22725699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
